Lung cancer survival has a headline figure that gets repeated in board presentations, grant applications, and hospital marketing materials: 92% ten-year survival for stage I disease found through screening. The number comes from the International Early Lung Cancer Action Program, published in the New England Journal of Medicine in 2006. It is real, it is remarkable, and it belongs to a specific group of patients who were diagnosed and operated on within one month.
Most programs repeat the 92% and stop there. The productive question is what it takes to replicate it, because the answer involves a set of intervals most health systems are not measuring and a patient population most programs are not reaching.




